Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — MYnd Analytics — IPO Roadshow (June 2017)
25 slides from Emmaus Life Sciences's IPO roadshow presentation, Jun 19, 2017
Slide 1: Predictive Medicine for Mental Health – Investor Presentation
PREDICTIVE MEDICINE FOR MENTAL HEALTH Investor Presentation June 2017
Slide 2: Forward-looking statements
This presentation contains “forward - looking statements” pursuant to the safe - harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation a
Slide 3: Public Offering Summary
Issuer: MYnd Analytics, Inc. (OTCQB: MYAN) Proposed Exchange / Ticker: NASDAQ Capital Market / MYND and MYND.W Securities Offered: • $9,000,000 of common stock • 50% warrant coverage Over - allotment: 15% (100% primary shares) Common Stock Outstanding Before the Offering: 2,539,061 shares Closing Pr
Slide 4: MYnd Analytics business and technology platform
• MYnd Analytics is a predictive analytics company that develops decision support tools to guide personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, and post - traumatic stress disorder (PTSD) Our Business • MYnd’s Psychiatric Electroencephalography Evalu
Slide 5: Board of Directors and management
Board of Directors Investor Presentation 5 George C. Carpenter – President & CEO • Over 25 years of experience in healthcare technology and business development • MBA in Finance from the University of Chicago, BA from Dartmouth College Brian MacDonald – Chief Technology Officer • Responsible for mac
Slide 6: Mental Health - Incidence & Cost
• Globally, an estimated 300 million people suffer from depression and 60 million have Bipolar affective disorder (1) • Anxiety disorders are the most common mental illness in the U.S. affecting 40 million adults (2) • It is estimated that 129 million children globally have Attention - deficit/hyper
Slide 7: MHSUD U.S. Spending
• Mental disorders, including substance abuse, have the highest estimated annual health spending in the U.S. • In 2013, healthcare spending on mental disorders reached $201 Billion (1) MENTAL HEALTH & SUBSTANCE USE DISORDERS (MHSUD) U.S. SPENDING Investor Presentation 7 Source: “Mental Disorders Top
Slide 8: Impact of MHSUD on Common High Cost Medical Conditions
Source: Melek S., Norris D., Paulus J.: Economic Impact of Integrated Medical - Behavioral Healthcare: Implications for Psychiatry. Prepared for APA; 2014, pp.1 - 39. Investor Presentation 8 Population % with Behavioral Health (BH) Diagnosis Per - member per - month (PMPM) cost without BH Diagnosis
Slide 9: Mental Health Medications Are Second Most Prescribed Therapeutic Class
Dispensed Prescriptions (in millions) 2011 20 1 2 2013 2014 2015 US Market 4,0 1 4 4,1 5 5 4, 2 36 4 , 32 5 4,3 6 8 Antihypertensives 649 691 701 705 706 Mental Health 495 511 523 537 547 Pain 4 7 2 484 481 483 470 Source: IMS Health, National Prescription Audit, Dec. 2015. MENTAL HEALTH MEDICATIONS
Slide 10: Trial and Error Pharmacotherapy
TRIAL AND ERROR PHARMACOTHERAPY Investor Presentation 10 “Current medications are not sufficient for most patients... We still do not know who will respond to a specific treatment. Even for the fraction of patients who ultimately respond, clinicians often must resort to trial and error before findin
Slide 11: Mental Health Market: Significant Unmet Need
MENTAL HEALTH MARKET: SIGNIFICANT UNMET NEED Of all people living with mental disorders • 12% are treated by a psychiatrist • 20% are treated by a mental health physician • 40 % are treated by a healthcare professional • 60% get no formal treatment Investor Presentation 11
Slide 12: Proprietary Outcomes Registry
PROPRIETARY OUTCOMES REGISTRY Investor Presentation 12 MYnd Clinical Registry 10,200+ Unique Patients 38,000+ Total Outcomes • Strong intellectual property protection with 22 issued patents and 1 patent pending • Technical know - how and proprietary algorithm developed and owned by MYnd • First move
Slide 13: Growing Evidence
“ EEG recording and analysis is currently experiencing a renaissance in interest and in both range and depth of applications, particularly in the search for endo - phenotypes and biomarkers for etiologic factors, individual diagnosis, risk for disorder, and treatment response.” Use of EEG Biomarkers
Slide 14: Can Technology Reduce Trial and Error?
“Technology CAN make a difference for mental health care. Digital phenotyping, like what PEER does with EEG, or with wearables or smartphone technology, can capture precise, continuous, objective measures of behavior… that’s a game changer for Psychiatry, and actually for the whole field of mental h
Slide 15: Current Technologies Used to Guide Treatment
Category Clinical Practice Application Examples Functional imaging Identifies brain regions associated with cognitive impairments, hyper/hypoactivation; no regulatory clearance for MH Amen Clinics Pharmacogenomic (PGx) testing CLIA Lab Developed Tests show activity of enzymes which impact drug metab
Slide 16: The Process
Patient and Doctor agree PEER is needed (can be a Psychiatrist or Primary Care Physician) An EEG test measures the patient’s unique brain patterns. The test is non - invasive , inexpensive, widely available and has a reimbursement code Patient’s EEG is compared to PEER database, which improves with
Slide 17: Interim Findings from the 4th Clinical Trial – Walter Reed PEER Trial
• Patients had a median of 5 visits compared to 2 visits for patients whose physicians used PEER as compared to those that did not follow PEER 144% 75% 75% 139% Depression Suicidality Global Improvement P T S P e r c e n t (1) VA/DOD Clinical Practice Guideline for Management of Major Depressive Dis
Slide 18: Commercialization Strategy
COMMERCIALIZATION STRATEGY Managed Care Payers and health systems seeking to improve clinical outcomes and lower health care costs VA/Military Where suicide rates are high and need for innovative and effective mental health care is high Provider Direct Multi - practitioner provider groups seeking to
Slide 19: Milestones Over Next Months
MILESTONES OVER NEXT 12 MONTHS Investor Presentation 19 1 Establish paid pilot program(s) with managed care companies and health systems seeking to improve clinical outcomes and lower health care costs 2 Show pharmacoeconomic benefits when providers use the PEER report on - line tool 3 Penetrate VA
Slide 20: Additional Service Lines
ADDITIONAL SERVICE LINES Problem Looming crisis in access to care • Psychiatrist shortage • Waiting lists are high • 70% of mental health is treated by PCPs • Waste due to low attendance and adherence to treatment (avg = 2 visits) Impact: • Over half of patients never seek treatment • Treatments the
Slide 21: Digital Health Care: Investments
MYND is in one of the hottest areas of AI/digital health care DIGITAL HEALTH CARE: INVESTMENTS Investor Presentation 21
Slide 22: Financial Summary and Capitalization
Common shares 2,528,0 6 1 61 . 0 % Options 348 , 09 5 8 . 4 % Warrant s (2) 1,270,9 2 6 30 . 6 % Fully - diluted shares outstanding 4 , 147 , 0 8 2 100 . 0 % Investor Presentation 22 (U.S. dollars) As of March 31, 2017 Cash and cash equivalents $1 , 754 , 40 0 Total assets 2,430, 1 0 0 Total liabili
Slide 23: Digital Health Care acquisitions
Source: RockHealth, 2016 https://rockhealth.com/reports/digital - health - exits - 2016 - ytd - 112 - digital - health - acquisitions - and - two - ipos/. Investor Presentation 23 Target Acquired By Acquisition Amount Change Healthcare McKesson $3.0B Truven Analytics IBM $2.6B eResearchTechnology No
Slide 24: Investment highlights
• CLINICAL NEED: Mental disorders are one of the greatest causes of disability and one of the main reasons why people miss work • MARKET OPPORTUNITY : $21 billion are spent annually on mental health medications making them the second most commonly prescribed therapeutic class behind anti - hypertens
Slide 25: Contact
Robin L. Smith, MD, MBA, Chairman of the Board tel: 917 - 691 - 7409 email: robin@robinlsmith.com George C. Carpenter IV , President and Chief Executive Officer tel: 949 - 697 - 2161 email: gcarpenter@myndanalytics.com Don D’Ambrosio Chief Financial Officer tel: 949 - 420 - 4402 email: ddambrosio@my